Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

JAK2 , As Well As PDL1 and PDL2 , are Recurrently Targeted by 9p24 Structural and Numerical Aberrations in Lymphoid Neoplasms of Both B- and T-Cell Origin

Katrien Van Roosbroeck, PhD, Thomas Tousseyn, MD PhD, Julio Finalet Ferreiro, M Sc, Idoya Lahortiga, PhD, Lucienne Michaux, MD PhD, Barbara Cauwelier, PhD, Barbara Pienkowska-Grela, PhD, Gregor Verhoef, Chantal Doyen, MD, Ivan Theate, MD, Christiane De Wolf-Peeters, MD PhD, Peter Vandenberghe, MD, PhD, Iwona Wlodarska, PhD

Blood (2011) 118 (21): 2460.

https://doi.org/10.1182/blood.V118.21.2460.2460

Published: 2011

Journal Articles

JAK2 rearrangements, including the novel SEC31A-JAK2 fusion, are recurrent in classical Hodgkin lymphoma

Katrien Van Roosbroeck, Luk Cox, Thomas Tousseyn, Idoya Lahortiga, Olga Gielen, Barbara Cauwelier, Pascale De Paepe, Gregor Verhoef, Peter Marynen, Peter Vandenberghe, Chris De Wolf-Peeters, Jan Cools, Iwona Wlodarska

Blood (2011) 117 (15): 4056–4064.

https://doi.org/10.1182/blood-2010-06-291310

Published: 2011

Includes: Supplemental data

Journal Articles

JAK2 Rearrangements, Including the Novel SEC31A-JAK2 Fusion, Are Recurrent in Classical Hodgkin Lymphoma.

Katrien Van Roosbroeck, Luk Cox, PhD, Idoya Lahortiga, PhD, Olga Gielen, Thomas Tousseyn, MD, PhD, Barbara Cauwelier, PhD, Pascale De Paepe, MD, PhD, Peter Vandenberghe, MD, PhD, Peter Marynen, PhD, Chris De Wolf-Peeters, MD, PhD, Jan Cools, PhD, Iwona Wlodarska, PhD

Blood (2009) 114 (22): 140.

https://doi.org/10.1182/blood.V114.22.140.140

Published: 2009

Journal Articles

Deletion of the Protein Tyrosine Phosphatase Gene PTPN2 in T-Cell Acute Lymphoblastic Leukemia.

Maria Kleppe, Idoya Lahortiga, PhD, Tiama El Chaar, Kim De Keersmaecker, PhD, Nicole Mentens, Carlos Graux, MD, PhD, Katrien Van Roosbroeck, Adolfo A. Ferrando, MD, PhD, Anton W Langerak, PhD, Jules P.P. Meijerink, PhD, Francois Sigaux, MD, Torsten Haferlach, MD, Iwona Wlodarska, PhD, Peter Vandenberghe, MD, PhD, Jean Soulier, MD, PhD, Jan Cools, PhD

Blood (2009) 114 (22): 141.

https://doi.org/10.1182/blood.V114.22.141.141

Published: 2009

Journal Articles

MYB Overexpression Is Directly Involved in Acute Myeloid Leukemia Pathogenesis and Could Constitute a New Therapeutic Target for Patients with Aberrant Expression of This Gene.

Carmen Vicente, Ph.D., Ana Conchillo, Ph.D., Daphnie Pauwels, BSc, Iria Vazquez, Ph.D., Laura Garcia-Orti, BSc, Maria J. Calasanz, Ph.D., Idoya Lahortiga, Ph.D., Jan Cools, Ph.D., Maria D. Odero, MD, Ph.D.

Blood (2009) 114 (22): 2402.

https://doi.org/10.1182/blood.V114.22.2402.2402

Published: 2009

Journal Articles

Sorafenib Potently Inhibits ETV6-PDGFRβ and FLT3 Mutants, and Shows Activity Against FLT3 Mutants That Are Resistant to Other Small Molecule Inhibitors.

Els Lierman, BSc, Idoya Lahortiga, PhD, Helen Van Miegroet, Nicole Mentens, Peter Marynen, PhD, Jan Cools, PhD

Blood (2006) 108 (11): 1993.

https://doi.org/10.1182/blood.V108.11.1993.1993

Published: 2006

Journal Articles

Array-CGH Analysis of T-ALL Patients and Cell Lines.

Idoya Lahortiga, PhD, Carlos Graux, MD, Nicole Mentens, Katrien Van Roosbroeck, Kim De Keersmaecker, Frederic Lambert, MD, Peter Vandenberghe, MD, Iwona Wlodarska, PhD, Guy Froyen, PhD, Maria D. Odero, PhD, MD, Peter Marynen, PhD, Jan Cools, PhD

Blood (2006) 108 (11): 4469.

https://doi.org/10.1182/blood.V108.11.4469.4469

Published: 2006

Journal Articles

GATA2 May Contribute with EVI1 to the Leukemogenic Mechanism in Patients with 3q21q26 Rearrangements.

Iria Vazquez, BSc, Idoya Lahortiga, PhD, Nerea Marcotegui, BSc, Maria Jose Larrayoz, BSc, Carmen Vicente, BSc, Jesus Maria Hernandez, MD, Jose Cervera, MD, Maria Jesus Vidal, MD, Jose A. Marquez, MD, Maria Jose Calasanz, PhD, Maria Dolores Odero, MD, PhD

Blood (2005) 106 (11): 2852.

https://doi.org/10.1182/blood.V106.11.2852.2852

Published: 2005

Journal Articles

GATA2 Is Overexpressed in 46% of Patients with AML and Normal Karyotype. The Mutational Pattern FLT3-ITD/GATA2/WT1 Could Define a Group of Patients with Normal Karyotype and AML-M1 Subtype.

Idoya Lahortiga, PhD, Iria Vazquez, BSc, Nerea Marcotegui, BSc, Eva Bandres, PhD, Raquel Malumbres, PhD, Maria J. Larrayoz, BSc, Carmen Vicente, BSc, Jose Cervera, MD, PhD, Jesus M. Hernandez, MD, PhD, Jesus Garcia-Foncillas, MD, PhD, Maria T. Ardanaz, MD, Filomena Floristan, MD, Maria J. Calasanz, PhD, Maria D. Odero, MD, PhD

Blood (2005) 106 (11): 2378.

https://doi.org/10.1182/blood.V106.11.2378.2378

Published: 2005

Journal Articles

A Gain of Function Mutation in JAK2 Is Frequently Found in Patients with AML-M2 and Normal Karyotype.

Nerea Marcotegui, BSc, Idoya Lahortiga, PhD, Iria Vazquez, BSc, Jose L. Vizmanos, PhD, Ion Cristobal, BSc, Cristina Ormazabal, BSc, Eva Bandres, PhD, Maria J. Larrayoz, BSc, Carmen Vicente, BSc, Maria J. Calasanz, PhD, María D. Odero, MD, PhD

Blood (2005) 106 (11): 2366.

https://doi.org/10.1182/blood.V106.11.2366.2366

Published: 2005

NARROW

JAK2 , As Well As PDL1 and PDL2 , are Recurrently Targeted by 9p24 Structural and Numerical Aberrations in Lymphoid Neoplasms of Both B- and T-Cell Origin

JAK2 rearrangements, including the novel SEC31A-JAK2 fusion, are recurrent in classical Hodgkin lymphoma

JAK2 Rearrangements, Including the Novel SEC31A-JAK2 Fusion, Are Recurrent in Classical Hodgkin Lymphoma.

Deletion of the Protein Tyrosine Phosphatase Gene PTPN2 in T-Cell Acute Lymphoblastic Leukemia.

MYB Overexpression Is Directly Involved in Acute Myeloid Leukemia Pathogenesis and Could Constitute a New Therapeutic Target for Patients with Aberrant Expression of This Gene.

Sorafenib Potently Inhibits ETV6-PDGFRβ and FLT3 Mutants, and Shows Activity Against FLT3 Mutants That Are Resistant to Other Small Molecule Inhibitors.

Array-CGH Analysis of T-ALL Patients and Cell Lines.

GATA2 May Contribute with EVI1 to the Leukemogenic Mechanism in Patients with 3q21q26 Rearrangements.

GATA2 Is Overexpressed in 46% of Patients with AML and Normal Karyotype. The Mutational Pattern FLT3-ITD/GATA2/WT1 Could Define a Group of Patients with Normal Karyotype and AML-M1 Subtype.

A Gain of Function Mutation in JAK2 Is Frequently Found in Patients with AML-M2 and Normal Karyotype.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only